相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®-ON
Jin Woo Song et al.
RESPIROLOGY (2020)
Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON
Bruno Crestani et al.
LANCET RESPIRATORY MEDICINE (2019)
Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis
Motoyasu Kato et al.
SCIENTIFIC REPORTS (2019)
Medication persistence rates and predictive factors for discontinuation of antifibrotic agents in patients with idiopathic pulmonary fibrosis: a real-world observational study
Keiji Oishi et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2019)
Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension
Luca Richeldi et al.
THORAX (2018)
Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials
Arata Azuma et al.
RESPIROLOGY (2017)
Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis
Satoshi Ikeda et al.
SCIENTIFIC REPORTS (2017)
Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials
Luca Richeldi et al.
RESPIRATORY MEDICINE (2016)
Predicting Survival Across Chronic Interstitial Lung Disease The ILD-GAP Model
Christopher J. Ryerson et al.
CHEST (2014)
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Talmadge E. King et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
An Official ATS/ERSARS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer
M. Reck et al.
ANNALS OF ONCOLOGY (2011)
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
Frank Hilberg et al.
CANCER RESEARCH (2008)
Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis
Hisashi Oku et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis
N. I. Chaudhary et al.
EUROPEAN RESPIRATORY JOURNAL (2007)
分享论文
